Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B
Edward Gane1, Stephen Locarnini2, Tien Huey Lim3, Simone Strasser4, William Sievert5, Wendy Cheng6,7, Alex Thompson8, Bruce Given9, Thomas Schluep9, James Hamilton9, Michael Biermer10, Ronald Kalmeijer11, Maria Beumont11, Oliver Lenz10,Gavin Cloherty12, Danny Ka-Ho Wong13, Christian Schwabe1, Kathy Jackson2, Carlo Ferrari14, Ching Lung Lai13, Robert G. Gish15, Man-Fung Yuen131Auckland Clinical Studies, Auckland, New Zealand; 2Victorian Infectious Diseases Reference Laboratory, Victoria, Australia; 3Middlemore Hospital, Auckland, New Zealand; 4Royal Prince Alfred Hospital, Sydney, Australia; 5Monash Health and Monash University, Melbourne, Australia; 6Royal Perth Hospital, Perth, Australia; 7Linear Clinical Research, Perth, Australia; 8St. Vincent's Hospital, Melbourne,Australia; 9Arrowhead Pharmaceuticals, Pasadena, CA, USA; 10Janssen Pharmaceuticals BV, Beerse, Belgium; 11Janssen R&D, Titusville, NJ, USA; 12Abbott Diagnostics, Abbott Park, IL, USA; 13The University of Hong Kong, Hong Kong, China; 14University of Parma, Parma, Italy; 15Hepatitis B Foundation, Doylestown, PA, USA
